Vistagen Therapeutics (MEX:VTGN) Cyclically Adjusted Book per Share: MXN114.63 (As of Mar. 2026)


MEX:VTGN Vistagen Therapeutics Inc MEX:VTGN
40 GF Score
Price MXN10.65
GF Value MXN103.67
! 3 Warning Signs
View Full Analysis

What is Vistagen Therapeutics Cyclically Adjusted Book per Share?

Vistagen Therapeutics MEX:VTGN 40 Cyclically Adjusted Book per Share is MXN114.63 as of Mar. 2026. GuruFocus rates MEX:VTGN with a GF Score™ of 40/100 and a GF Value™ of MXN103.67. The stock has 3 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

Vistagen Therapeutics's adjusted book value per share for the three months ended in Mar. 2026 was MXN16.167. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is MXN114.63 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Vistagen Therapeutics's average Cyclically Adjusted Book Growth Rate was 448.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Book Growth Rate of Vistagen Therapeutics was 29.30% per year. The lowest was 1.70% per year. And the median was 9.75% per year.

As of today (2026-07-01), Vistagen Therapeutics's current stock price is MXN10.65. Vistagen Therapeutics's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2026 was MXN114.63. Vistagen Therapeutics's Cyclically Adjusted PB Ratio of today is 0.09.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Vistagen Therapeutics was 2.30. The lowest was 0.04. And the median was 0.96.


Vistagen Therapeutics  (MEX:VTGN) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Vistagen Therapeutics's Cyclically Adjusted PB Ratio of today is calculated as

Cyclically Adjusted PB Ratio=Share Price/Cyclically Adjusted Book per Share
=10.65/114.63
=0.09

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Vistagen Therapeutics was 2.30. The lowest was 0.04. And the median was 0.96.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


Vistagen Therapeutics Cyclically Adjusted Book per Share Related Terms


Vistagen Therapeutics Cyclically Adjusted Book per Share Historical Data

* Premium members only.

The historical data trend for Vistagen Therapeutics's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Vistagen Therapeutics Cyclically Adjusted Book per Share Chart

Vistagen Therapeutics Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 114.63

Vistagen Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 114.63

MEX:VTGN vs PSTV, KYNB, TVGN: Cyclically Adjusted Book per Share Comparison

For the Biotechnology subindustry, Vistagen Therapeutics's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Vistagen Therapeutics Cyclically Adjusted PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Vistagen Therapeutics's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Vistagen Therapeutics's Cyclically Adjusted PB Ratio falls into.


MEX:VTGN
40GF Score
Vistagen Therapeutics Inc MEX:VTGN
Cyclically Adjusted Book per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Vistagen Therapeutics Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Vistagen Therapeutics's adjusted Book Value per Share data for the three months ended in Mar. 2026 was:

Adj_Book= Book Value per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=16.167/330.2130*330.2130
=16.167

Current CPI (Mar. 2026) = 330.2130.

Vistagen Therapeutics Quarterly Data

Book Value per Share CPI Adj_Book
201606 428.199 241.018 586.665
201609 286.040 241.428 391.231
201612 186.346 241.432 254.870
201703 39.064 243.801 52.910
201706 -35.626 244.955 -48.026
201709 -78.392 246.819 -104.879
201712 267.571 246.524 358.405
201803 164.387 249.554 217.519
201806 82.226 251.989 107.751
201809 78.380 252.439 102.528
201812 32.011 251.233 42.074
201903 96.526 254.202 125.389
201906 21.926 256.143 28.266
201909 -50.487 256.759 -64.930
201912 -78.037 256.974 -100.278
202003 -81.968 258.115 -104.864
202006 -69.693 257.797 -89.270
202009 37.779 260.280 47.930
202012 403.715 260.474 511.805
202103 312.251 264.877 389.273
202106 266.992 271.696 324.496
202109 253.314 274.310 304.938
202112 238.331 278.802 282.279
202203 187.152 287.504 214.954
202206 134.447 296.311 149.830
202209 86.368 296.808 96.089
202212 58.443 296.797 65.023
202303 29.783 301.836 32.583
202306 14.910 305.109 16.137
202309 51.690 307.789 55.456
202312 77.435 306.746 83.359
202403 70.184 312.332 74.202
202406 70.967 314.175 74.590
202409 67.665 315.301 70.865
202412 59.747 315.605 62.512
202503 49.662 319.799 51.279
202506 36.502 322.561 37.368
202509 31.291 324.800 31.812
202512 23.141 324.054 23.581
202603 16.167 330.213 16.167

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

What does a Cyclically Adjusted Book per Share of MXN114.63 mean?
Vistagen Therapeutics (MEX:VTGN) has a Cyclically Adjusted Book per Share of MXN114.63 as of Mar. 2026. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Vistagen Therapeutics and its competitors.
Is Vistagen Therapeutics' Cyclically Adjusted Book per Share too high?
Vistagen Therapeutics' current Cyclically Adjusted Book per Share is MXN114.63. Overall, Vistagen Therapeutics has a GF Score™ of 40/100, reflecting its overall financial health beyond just this single metric.
How does Vistagen Therapeutics' Cyclically Adjusted Book per Share compare to PSTV and KYNB?
Vistagen Therapeutics' Cyclically Adjusted Book per Share of MXN114.63 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Book per Share for a Biotechnology company?
A good Cyclically Adjusted Book per Share depends on the Biotechnology industry context. However, Cyclically Adjusted Book per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Book per Share mean?
A high Cyclically Adjusted Book per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Vistagen Therapeutics and its competitors. Vistagen Therapeutics's current Cyclically Adjusted Book per Share is MXN114.63. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vistagen Therapeutics stock overvalued right now?
Vistagen Therapeutics (MEX:VTGN) has a current Cyclically Adjusted Book per Share of MXN114.63. The stock's GF Value™ is MXN103.67, compared to a current price of MXN10.65 — trading 89.7% below its estimated fair value. The current Cyclically Adjusted Book per Share is MXN114.63. Vistagen Therapeutics' overall GF Score™ is 40/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Book per Share calculated?
Cyclically Adjusted Book per Share is calculated from a company's financial statements. For Vistagen Therapeutics (MEX:VTGN), the current Cyclically Adjusted Book per Share is MXN114.63 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Vistagen Therapeutics (MEX:VTGN) Overvalued in 2026?

Based on GuruFocus' analysis, Vistagen Therapeutics stock appears to be undervalued. The current stock price of MXN10.65 is trading 89.7% below its estimated GF Value™ of MXN103.67.

Key valuation signals for MEX:VTGN:

  • Cyclically Adjusted Book per Share: MXN114.63
  • GF Value™: MXN103.67 vs. price of MXN10.65 (89.7% below fair value)
  • GF Score™: 40/100 with 3 warning signs

No single metric tells the full story. See the MEX:VTGN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Vistagen Therapeutics Business Description

Other Exchanges VTGN:USA
Address 343 Allerton Avenue, South San Francisco, CA, USA, 94080
Vistagen Therapeutics Inc is a late clinical-stage therapeutics company focused on developing and commercializing medicines for patients with social anxiety disorder, depression, menopausal hot flashes, psychomotor impairment due to mental fatigue, and cancer cachexia. The company is engaged in developing intranasal product candidates called pherines, which leverage the understanding of nose-to-brain neurocircuitry. Vistagen's pherine pipeline consists of various product candidates like: Fasedienol, Itruvone, PH15, Refisolone, and PH284, which are being developed to provide treatment for a variety of disorders. Additionally, it is seeking potential partners for the further clinical development and commercialization of an oral drug candidate, AV-101, to treat certain neurological disorders.
40GF Score

Get the complete analysis for MEX:VTGN

Cyclically Adjusted Book per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN10.65
Price
MXN103.67
GF Value